PASW:NASDAQPing An Biomedical Co., Ltd. Analysis

Technical outlook: The stock sits just above its recent support of $0.131 and below a resistance near $0.176. Momentum indicators are mixed – the 14‑day RSI sits at 62, suggesting the price is approaching overbought territory, while the MACD line has turned bullish (MACD histogram positive). Volume is increasing and the market sentiment index reads “Extreme Greed” at 93, indicating short‑term buying pressure.
Fundamental reality: Behind the technical bounce, the company is in severe distress: revenue has collapsed by 62% year‑over‑year, gross margin is a meager 2.8% and operating margin is –70%. Cash flow is negative, with a free‑cash‑flow deficit exceeding $59 M and a debt‑to‑equity ratio of over 23, implying a heavily leveraged balance sheet. The price‑to‑book (0.52) and price‑to‑sales (0.62) ratios are low, but the max drawdown of –96% and a beta of 1.15 underscore extreme volatility and market risk.